A cost-effectiveness framework to evaluate a predictive companion diagnostics of selecting men with high risk localized prostate cancer for neoadjuvant or adjuvant chemotherapy in the u.s.
PDF
PDF format is widely accepted and good for printing.
PDF-1(1.93 MB)

Citation & Export
Hide

Simple citation

He, Jimmy. A cost-effectiveness framework to evaluate a predictive companion diagnostics of selecting men with high risk localized prostate cancer for neoadjuvant or adjuvant chemotherapy in the u.s. Retrieved from https://doi.org/doi:10.7282/T34J0GZ6

Export

Statistics
Hide